Holen Sie sich die Stockscreener-App
2.27
3.65%
0.08
Handel nachbörslich:
2.27
Schlusskurs vom Vortag:
$2.19
Offen:
$2.16
24-Stunden-Volumen:
62,996
Relative Volume:
0.40
Marktkapitalisierung:
$78.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-28.30M
KGV:
-3.3466
EPS:
-0.6783
Netto-Cashflow:
$-21.30M
1W Leistung:
-2.58%
1M Leistung:
-8.84%
6M Leistung:
-0.44%
1J Leistung:
-82.95%
1-Tages-Spanne:
$2.15
$2.31
1-Wochen-Bereich:
$2.13
$2.43
52-Wochen-Spanne:
$1.60
$16.60
Genelux Corp Stock (GNLX) Company Profile
Firmenname
Genelux Corp
Sektor
Branche
Telefon
805-267-9889
Adresse
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Vergleichen Sie GNLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.27 | 78.40M | 0 | -28.30M | -21.30M | -1.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-29 | Eingeleitet | Guggenheim | Buy |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-11-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-09-12 | Eingeleitet | Maxim Group | Buy |
| 2023-02-15 | Eingeleitet | The Benchmark Company | Speculative Buy |
Genelux Corp Aktie (GNLX) Neueste Nachrichten
Genelux CEO Zindrick Thomas sells $33,497 in stock - Investing.com
Genelux CEO Zindrick Thomas sells $33,497 in stock By Investing.com - Investing.com UK
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright - Yahoo Finance
HC Wainwright Cuts Genelux (NASDAQ:GNLX) Price Target to $30.00 - Defense World
Genelux shares target cut, maintains buy rating on 3Q earnings - Investing.com
Genelux reports Q3 EPS (19c), consensus (19c) - TipRanks
Genelux Reports $6.5M Q3 Loss, Advances Lung Cancer Trials with $35.1M Cash Runway - StockTitan
Genelux Corp. Releases New Corporate Presentation - TipRanks
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference - Yahoo Finance
Genelux CEO to Present at Guggenheim Healthcare Innovation Conference - StockTitan
Individual investors who hold 56% of Genelux Corporation (NASDAQ:GNLX) gained 34%, institutions profited as well - Yahoo Finance
Guggenheim Begins Coverage on Genelux (NASDAQ:GNLX) - Defense World
Guggenheim sees upside in Genelux shares, targets $8 as pivotal cancer trial progresses - Investing.com India
Brokerages Set Genelux Co. (NASDAQ:GNLX) PT at $22.33 - MarketBeat
Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp - Yahoo Finance
Genelux doses first subject in Phase II trial of NSCLC treatment - Yahoo Finance
Genelux advances NSCLC treatment with Phase 2 Olvi-Vec trial - Investing.com
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer - Yahoo Finance
Cubist Systematic Strategies LLC Takes $56,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux Co. (NASDAQ:GNLX) Shares Sold by Renaissance Technologies LLC - Defense World
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit - Yahoo Finance
Genelux announces executive departure By Investing.com - Investing.com Australia
Genelux announces executive departure - Investing.com
Point72 Asia Singapore Pte. Ltd. Acquires Shares of 20,162 Genelux Co. (NASDAQ:GNLX) - Defense World
Affinity Asset Advisors LLC Acquires New Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Highbridge Capital Management LLC Invests $1.23 Million in Genelux Co. (NASDAQ:GNLX) - Defense World
Short Interest in Genelux Co. (NASDAQ:GNLX) Decreases By 7.3% - MarketBeat
Genelux corp insider sells over $170k in company stock - Investing.com India
Genelux director Tyree James L sells shares worth over $4,400 - Investing.com India
Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells $63,134.10 in Stock - MarketBeat
Genelux corp insider sells over $196k in company stock - Investing.com
ROTH MKM analysts initates a Buy rating for Genelux Corp (GNLX) - Knox Daily
Genelux Corp insider sells $89.6k in company stock By Investing.com - Investing.com Australia
Genelux Corp insider sells $89.6k in company stock - Investing.com India
Insider Selling: Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells 42,818 Shares of Stock - MarketBeat
Genelux Corp [NASDAQ: GNLX] Sees Increase in Stock Value - Knox Daily
Genelux Corp (GNLX) Stock: A Year of Decreases and Increases - The InvestChronicle
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference - Yahoo Finance
Genelux Corp (GNLX) may enjoy gains as insiders got busy in the recent days - Knox Daily
Aladar Szalay Sells 107,045 Shares of Genelux Co. (NASDAQ:GNLX) Stock - Defense World
Genelux Corp insider sells over $550k in company stock - Investing.com India
Analysts Set Genelux Co. (NASDAQ:GNLX) Price Target at $26.75 - MarketBeat
Genelux (NASDAQ:GNLX) Upgraded to Strong-Buy by Roth Capital - Defense World
Genelux Corp [GNLX] Insider Activity: An Update for Investors - Knox Daily
Genelux Co. (NASDAQ:GNLX) Major Shareholder Aladar Szalay Sells 40,000 Shares - Defense World
Genelux (NASDAQ:GNLX) Receives New Coverage from Analysts at Roth Mkm - Defense World
Genelux (NASDAQ:GNLX) Coverage Initiated at Roth Mkm - MarketBeat
Genelux shares gain on Roth/MKM Buy rating, $10 price target - Investing.com
Genelux initiated with a Buy at Roth MKM - TipRanks
Equities Analysts Offer Predictions for Genelux Co.’s Q3 2024 Earnings (NASDAQ:GNLX) - Defense World
Genelux Co. (NASDAQ:GNLX) Sees Large Decrease in Short Interest - MarketBeat
Finanzdaten der Genelux Corp-Aktie (GNLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Genelux Corp-Aktie (GNLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Zak Lourie S. | Chief Financial Officer |
Dec 16 '24 |
Sale |
2.34 |
2,103 |
4,921 |
40,802 |
| Smalling Ralph | Head of Regulatory |
Dec 16 '24 |
Sale |
2.34 |
2,510 |
5,873 |
16,322 |
| Cappello Joseph | VP, Pharmaceutical Development |
Dec 16 '24 |
Sale |
2.34 |
6,300 |
14,742 |
14,653 |
| Szalay Aladar | 10% Owner |
Sep 12 '24 |
Sale |
2.73 |
31,777 |
86,732 |
632,901 |
| Szalay Aladar | 10% Owner |
Sep 13 '24 |
Sale |
2.57 |
33,080 |
84,946 |
599,821 |
| Tyree James L | Director |
Sep 11 '24 |
Sale |
2.60 |
1,730 |
4,499 |
47,521 |
| Szalay Aladar | 10% Owner |
Sep 11 '24 |
Sale |
2.62 |
31,376 |
82,227 |
664,678 |
| Szalay Aladar | 10% Owner |
Sep 09 '24 |
Sale |
2.70 |
23,383 |
63,200 |
716,438 |
| Szalay Aladar | 10% Owner |
Sep 10 '24 |
Sale |
2.51 |
20,384 |
51,182 |
696,054 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):